3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Conditions
Melanoma
14
Carcinoma, Renal Cell
10
Carcinoma, Non-Small-Cell Lung
7
Carcinoma, Transitional Cell
4
Neoplasms
3
Neoplasm Metastasis
3
Clear-cell metastatic renal cell carcinoma
3
Carcinoma, Hepatocellular
3
Thyroid Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Nasopharyngeal Carcinoma
2
Myelodysplastic Syndromes
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Kidney Neoplasms
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Urachal adenocarcinoma
1
Triple Negative Breast Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Somatostatinoma
1
Skin Neoplasms
1
Seminoma
1
Sarcoma
1
Interventions
Bevacizumab
25
Fluorouracil
23
Leucovorin
22
Cetuximab
22
Oxaliplatin
19
pembrolizumab
14
Specimen Handling
11
Irinotecan
10
Nivolumab
8
Magnetic Resonance Spectroscopy
8
Biopsy
7
atezolizumab
6
fludarabine
5
encorafenib
5
Pemetrexed
5
Panitumumab
5
HMPL-013
5
Gemcitabine
5
Folfox protocol
5
Cisplatin
5
Carboplatin
5
trifluridine tipiracil drug combination
4
balstilimab
4
Standard of Care
4
Immunoglobulin G
4
Disulfides
4
Cyclophosphamide
4
regorafenib
3
fludarabine phosphate
3
dehydroftorafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Ipilimumab
×
30 days
×
Clear all
NCT05176483
2026-05-27
STELLAR-002
Exelixis
Phase 1
Recruiting
1,314 enrolled